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Abstract
Hepatorenal Syndrome (HRS) is an important condition for clinicians to be 
aware of in the presence of cirrhosis. In simple terms, HRS is defined as a rela-
tive rise in creatinine and relative drop in serum glomerular filtration rate (GFR) 
alongside renal plasma flow (RPF) in the absence of other competing etiologies of 
acute kidney injury (AKI) in patients with hepatic cirrhosis. It represents the end 
stage complication of decompensated cirrhosis in the presence of severe portal 
hypertension, in the absence of prerenal azotemia, acute tubular necrosis or others. 
It is a diagnosis of exclusion. The recognition of HRS is of paramount importance 
for clinicians as it carries a high mortality rate and is an indication for transplan-
tation. Recent advances in understanding the pathophysiology of the disease 
improved treatment approaches, but the overall prognosis remains poor, with Type 
I HRS having an average survival under 2 weeks. Generally speaking, AKI and renal 
failure in cirrhotic patients carry a very high mortality rate, with up to 60% mortal-
ity rate for patients with renal failure and cirrhosis and 86.6% of overall mortality 
rates of patients admitted to the intensive care unit. Of the various etiologies of 
renal failure in cirrhosis, HRS carries a poor prognosis among cirrhotic patients 
with acute kidney injury. HRS continues to pose a diagnostic challenge. AKI can 
be either pre-renal, intrarenal or postrenal. Prerenal causes include hypovolemia, 
infection, use of vasodilators and functional due to decreased blood flow to the 
kidney, intra-renal such as glomerulopathy, acute tubular necrosis and post-renal 
such as obstruction. Patients with cirrhosis are susceptible to developing renal 
impairment. HRS may be classified as Type 1 or rapidly progressive disease, and 
Type 2 or slowly progressive disease. There are other types of HRS, but this chapter 
will focus on Type 1 HRS and Type 2 HRS. HRS is considered a functional etiology 
of acute kidney injury as there is an apparent lack of nephrological parenchymal 
damage. It is one several possibilities for acute kidney injury in patients with both 
acute and chronic liver disease. Acute kidney injury (AKI) is one of the most severe 
complications that could occur with cirrhosis. Up to 50% of hospitalized patients 
with cirrhosis can suffer from acute kidney injury, and as mentioned earlier an AKI 
in the presence of cirrhosis in a hospitalized patient has been associated with nearly 
a 3.5-fold increase in mortality. The definition of HRS will be discussed in this chap-
ter, but it is characterized specifically as a form of acute kidney injury that occurs 
in patients with advanced liver cirrhosis which results in a reduction in renal blood 
flow, unresponsive to fluids this occurs in the setting of portal hypertension and 
splanchnic vasodilation. This chapter will discuss the incidence of HRS, recognizing 
HRS, focusing mainly on HRS Type I and Type II, recognizing competing etiologies 
of renal impairment in cirrhotic patients, and the management HRS.
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1. Introduction
Hepatorenal Syndrome (HRS) is an important condition for clinicians to be 
aware of in the presence of cirrhosis. In simple terms, HRS is defined as a rela-
tive rise in creatinine and relative drop in serum glomerular filtration rate (GFR) 
alongside renal plasma flow (RPF) in the absence of other competing etiologies 
of acute kidney injury (AKI) in patients with hepatic cirrhosis [1–7]. It represents 
the end stage complication of decompensated cirrhosis in the presence of severe 
portal hypertension, in the absence of prerenal azotemia, acute tubular necrosis or 
others. It is a diagnosis of exclusion [2]. The recognition of HRS is of paramount 
importance for clinicians as it carries a high mortality rate. Recent advances in 
understanding the pathophysiology of the disease improved treatment approaches, 
but the overall prognosis remains poor, with Type I HRS having an average survival 
under 2 weeks [3]. Generally speaking, AKI and renal failure in cirrhotic patients 
carry a very high mortality rate, with up to 60% mortality rate for patients with 
renal failure and cirrhosis and 86.6% of overall mortality rates of patients admitted 
to the intensive care unit [4, 5]. Of the various etiologies of renal failure in cirrhosis, 
HRS carries a poor prognosis among cirrhotic patients with AKI.
HRS continues to pose a diagnostic challenge. AKI is relatively frequent, seen in 
about 20% of patients with cirrhosis [8]. AKI can be either pre-renal, intrarenal or 
postrenal. Prerenal causes include hypovolemia, infection, use of vasodilators and 
functional due to decreased blood flow to the kidney, intra-renal such as glomeru-
lopathy, acute tubular necrosis and post-renal such as obstruction. Patients with 
cirrhosis are susceptible to developing renal impairment. HRS may be classified 
as type 1 or rapidly progressive disease, and type 2 or slowly progressive disease. 
There are other types of HRS [9], but this chapter will focus on type 1 HRS and type 
2 HRS. HRS is considered a functional etiology of AKI as there is an apparent lack 
of nephrological parenchymal damage. This is one of several possibilities of AKI in 
patients with both acute and chronic liver disease.
AKI is one of the most severe complications that could occur with cirrhosis. Up 
to 50% of hospitalized patients with cirrhosis can suffer from AKI, and as men-
tioned earlier an AKI in the presence of cirrhosis in a hospitalized patient has been 
associated with nearly a 3.5-fold increase in mortality [6].
The definition of HRS will be discussed in this chapter, but it is characterized 
specifically as a form of AKI that occurs in patients with advanced liver cirrhosis 
which results in a reduction in renal blood flow, unresponsive to fluids this occurs in 
the setting of portal hypertension and splanchnic vasodilation [7].
This chapter will discuss the incidence, definitions and management of HRS, 
focusing mainly on HRS type I and type II.
2. Frequency of acute kidney injury in cirrhosis
AKI is a common entity in cirrhotic patients at baseline. It is also commonly seen 
in general hospitalized patients, both with and without cirrhosis. This fundamen-
tally means that a clinician should be able to distinguish various etiologies of AKI 
establish the reason for AKI in each cirrhotic patient so that management can be 
conducted appropriately.
As mentioned before, the frequency of AKI in patients with underlying liver 




cirrhosis. Of these patients, 19% found to have an AKI, out of these 23% found 
to have HRS [10]. “The AKI was divided into pre-renal, intrinsic, and post-renal. 
Pre-renal injury was the most common form of AKI which represented 68% of 
patients with AKI. The pre-renal injury was usually volume responsive, while HRS 
is non-volume responsive. In most cases, the injury was volume responsive and 
therefore less likely HRS [11, 12]. Although HRS is not always the most common 
cause of renal impairment in cirrhosis; renal impairment itself is commonly seen 
as the frequency of AKI in cirrhosis can vary in the literature from approximately 
15–40% [13–15].
The etiologies of AKI in cirrhosis vary, and the prognosis that each etiology 
carries also varies. One large prospective study found that hypovolemia and infec-
tions were in fact the most common culprits of AKI in cirrhosis, with HRS being 
identified in 13% of cases [16]. The definition of HRS is important as it can guide 
clinicians into decision making. For instance, if the etiology of an AKI in cirrhosis 
is reversible and will not cause significant long-term impairment, the urgency for 
immediate transplantation dissipates. Conversely, if there is the development of 
HRS, there may be urgent indication for transplantation.
While there are varying figures reported in the literature on the frequency of 
AKI in the cirrhotic population, it is evident that it is a common entity. Not all 
AKI in cirrhosis is considered HRS and defining HRS as the specific cause of renal 
impairment in cirrhosis represents another challenge for clinicians.
3. Defining hepato-renal syndrome
As stated previously, HRS is defined as renal impairment that occurs in patients 
who have clinically established cirrhosis or have significant liver impairment. The 
most widely used definition is the relative rise in creatinine and the relative drop in 
serum GFR and renal plasma flow in the absence of other causes of AKI like prere-
nal, renal or post-renal. Given its poor prognosis, HRS was formerly associated with 
the term terminal functional renal failure [17]. In theory, since there is no intrinsic 
kidney pathology, upon reversing the hepatic dysfunction either medically or via 
transplantation, there should be resolution of HRS. In intrinsic renal pathologies, 
this would not be the case. Before considering HRS, clinicians should rule out other 
competing etiologies.
4. Competing etiologies of hepatorenal syndrome
Differentiating HRS from other etiologies of AKI in cirrhotic patients is clini-
cally of high importance because of the pronounced difference in management 
and prognosis. Patients with liver cirrhosis are prone to have acute, subacute 
and chronic kidney disease through a variety of mechanisms. Clinicians should 
have a broad differential diagnosis when approaching patients with AKI as there 
is no definitive test for HRS yet [18]. It is therefore necessary to rule out other 
differential diagnosis before a diagnosis of HRS is made. Identification of risk 
factors and careful assessment of the renal system are the mainstay to make such 
a diagnosis.
Cirrhotic patients may have a certain level of renal insufficiency at baseline since 
some etiologies of cirrhosis can directly or indirectly lead to renal insufficiency. 
For instance, patients with non-alcoholic fatty liver disease have higher incidence 
of obesity and associated diabetes and diabetic nephropathy. Also, both glomerulo-
nephritis and vasculitis can occur in patients with liver cirrhosis secondary to viral 
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hepatitis [2]. These are just a few examples of how one pathology can affect both the 
hepatic and renal system.
Given the wide spectrum of possibilities, when approaching a renal impairment 
in a patient with cirrhosis, a systematic approach can be of benefit to clinicians to 
assess the nature of renal impairment. Causes of AKI and renal failure in cirrhotic 
patients can be summarized in four main categories.
4.1 Hypovolemia-induced renal failure
This is usually due to hemorrhage related to gastrointestinal bleed or fluid loss 
associated with excessive diuresis or diarrhea induced by excessive laxatives use 
[19]. Also, can be secondary to different infectious etiologies including spontaneous 
bacterial peritonitis. In any of these cases, renal failure will occur soon after any 
of the mentioned hypovolemic events [16, 19]. Due to the fact that patients with 
worsening liver cirrhosis will have decreased intravascular volume and mean arte-
rial resistance [17], hypovolemia should be considered as a frequent component of 
AKI in those patients [16]. The management of hypovolemia induced renal failure is 
to address the volume status.
4.2 Parenchymal renal disease
By definition HRS is a purely functional disease and it does not induce renal 
parenchymal damage. However, any parenchymal renal disease can occur in 
both cirrhotic patients and non-cirrhotic patients. The presence of proteinuria, 
hematuria or both is associated with glomerular disease. Differentiating HRS from 
acute Tubular Necrosis (ATN) remains difficult. While the presence of muddy 
brown casts favors ATN, other urinary indexes like fractional excretion of sodium 
(FeNa) can be misleading due to the prolonged use of diuretics in cirrhotic patients. 
Granular casts can be seen in both ATN and HRS [19].
4.3 Drug induced renal disease
Drug-induced tubular/tubulointerstitial injury is a common cause of AKI espe-
cially with the consideration ill patients such as those with cirrhosis will inevitably 
need medications. There are various pathways and in which a drug can cause renal 
injury [20]. Some examples can include aminoglycosides, vancomycin, and even 
administration of contrast needed for imaging studies.
4.4 Hepatorenal syndrome
HRS is a diagnosis of exclusion based on the previously mentioned criteria. This 
chart simplifies the definition based on the criteria set forth by the International 
Ascites Club [21, 22].
The key factor in diagnosing HRS is the absence of improvement of kidney 
function despite discontinuation of potential nephrotoxic agents, and a trial of 
fluid repletion. Essentially HRS appears as a non-volume responsive pre-renal 
injury. This is why it is essential to rule out all other possible AKI systematically 
(Table 1).
4.4.1 Diagnosis
AKI stage 1 is defined as the increase in serum creatinine (sCr) of >0.3 mg/dl 




baseline in the past 3 months which occurred within the past 7 days or urine 
volume < 0.5 cc/kg for 6 hours.
Changes in the definition of AKI in patients with cirrhosis has changed over 
time and has been replaced by the ICA (International Club of Ascites) AKI criteria 
[4, 23]. One of the most important changes was the removal of cutoff values of sCr 
for diagnosis of HRS in the setting of AKI, allowing earlier recognition and treat-
ment of HRS.
Major diagnostic criteria include cirrhosis with ascites, presence of renal failure 
which helps differentiate HRS type I and HRS type II.
4.4.1.1 HRS type I
HRS type 1, renal failure is acute based on the KDIGO guidelines, increase in 
serum creatinine by ≥0.3 mg/dL within 48 hours; Increase in serum creatinine to 
≥1.5 times baseline (i.e. 50% above baseline), which is known or presumed to have 
occurred within the prior 7 days; or urine volume < 0.5 mL/kg/h over a 6-hour 
period [23].
4.4.1.2 HRS type II
Type 2 HRS renal failure decline in renal function progresses more slowly, 
usually Cr >1.5. Diagnosis of HRS-type 2 be made either in the context of chronic 
kidney disease (CKD), that is, in a patient with cirrhosis and a GFR <60 ml/min per 
1.73 m2 for >3 months (HRS-CKD) in whom other causes have been excluded, or 
in the context of AKI, defined as a renal dysfunction that does not meet criteria for 
AKI and lasts for less than 90 days.
KDIGO guidelines define CKD as abnormalities in kidney structure or function 
(GFR <60 ml/min/1.72 m2) that persist for more than 90 days, and acute kidney 
disease (AKD), as AKI or as abnormalities in kidney structure or function that 
persist for more than 90 days [9, 23].
A recent proposal in the European association for the study of the liver guide-
lines suggested that HRS-2 should be referred to as HRS-NAKI (hepato-renal 
syndrome non-acute kidney injury) [24]. This is due to many reasons. HRS 2 is 
poorly defined and is more of an assumption that chronic abnormalities in serum 
creatinine without a definite timeline, thus arriving at a new definition of HRS-2 is 
more challenging than expected.
Defining hepatorenal syndrome
• Chronic or acute liver failure with signs of portal hypertension
• Low GFR
• Exclusion of shock
• Protienuria less than 0.5 grams per day with exclusion of obsrtuvtive uropathy and exclusion of 
parecnyhmal disease
• Failure of renal function improve with 1.5 liter isotonic volume - exapnsion and/or with discontiuation 
of diuretic
Additional criteria
• Urine volume less than 0.5 liters per day
• Low urine sodium (<10mmol/l), serum sodium <130mmol/l
• Less than 50 red blood cells per hpf on urine microscopy
Table 1. 
Defining Hepatorenal Syndrome. Adopted from International Ascites Club and in [21, 22].
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It is proposed that the diagnosis of HRS-NAKI be made either in the context of 
CKD, that is in a patient with cirrhosis and a decrease in GFR greater than 3 months 
(HRS-CKD) or in the context of AKD, defined as a renal dysfunction that does not 
meet criteria for AKI and lasts for less than 90 days underlying factors such as dia-
betes, arterial hypertension causing nonalcoholic steatohepatitis which eventually 
lead to cirrhosis can simultaneously affect the kidneys causing CKD as well [23].
The new nomenclature may enable clinicians to define the presence of HRS-
AKI superimposed on CKD in a patient with structural damage of the kidney, as 
evidenced by previous abnormal biopsy, renal ultrasonography or by significant 
proteinuria.
In the context of the new definition of HRS-AKI on CKD: HRS-AKI, there would 
be no evidence of chronic structural damage. For HRS-AKI on CKD in which there 
would be evidence of chronic structural damage such as chronic proteinuria and/or 
abnormal renal ultrasonography but with a high suspicion of HRS-AKI.
Other diagnostic criteria for hepatorenal syndrome include:
1. Failure of response to 48-hour volume expansion with albumin and discon-
tinuation of diuretics.
2. Absence of current use of nephrotoxic medications.
3. Absence of macroscopic indication of structural kidney injury such as of pro-
teinuria less than 500 mg per day, microhematuria (less than 50 red blood cells 
per high powered field) and normal kidney ultrasound [9, 21, 23] (Table 2).
4.4.2 Challenges in diagnosing hepatorenal syndrome
Although the definition of HRS appears straightforward, there are many clinical 
challenges to consider when making a diagnosis. For instance, the usefulness of 
creatinine measurement in patients with cirrhosis may be limited for many reasons 
such as assay interference with bilirubin, reduced creatinine production in liver 
failure patients, muscle wasting and malnutrition [25].
Also using the urine output in patients with cirrhosis is limited as it can affected 
by other factors, for example decreased urine can be a normal in hypovolemic 
patients as they retain sodium or it can be simply increased secondary to the use 
of diuretics, [26, 27] despite that urine output remain a factor to look for, as was 
demonstrated by, Amathieu et al. who showed that reduction in urine output is 
associated with worse prognosis and 3-fold increased in hospital mortality [28].
These are just a few examples of how clinicians must use sound judgment when 
attempting to make a diagnosis of HRS. As mentioned earlier, it is important to 
stratify causes as it would impact both management and possibly the urgency for 
transplantation.
4.5 ATN versus HRS
Differentiating ATN and HRS can also pose a challenge to clinicians. Pre-renal 
azotemia represents the leading cause of AKI in patients with cirrhosis, good his-
tory and physical examination of patients warranted to exclude causes of hypovole-
mia as discussed above.
Urine studies have been also sought to be helpful, with structural etiologies such 
as ATN, tubular injury limits sodium reabsorption and fraction excretion of sodium 
(FENa) is increased, typically by greater than 2–3%, using these cutoffs has been 




renal hypoperfusion and have an FENa less than 1%, even in the absence of AKI [29]. 
Other studies such as urinary sodium (less than 40 milliequivalents per liter), low 
urine osmolality are suggestive of ATN although their use in HRS has been limited.
The fraction excretion of urea (FEUrea) is superior to FeNA in differentiat-
ing AKI-HRS from ATN, obtaining such tests is very important in HRS as most 
patients with HRS are on diuretics. Urinary sodium is known to be affected by use 
of diuretic which can falsely elevate the urine sodium. That is one main reason why 
FeNa has been excluded from HRS definitions.
4.6 The role of biomarkers in diagnosing HRS
Novel urine biomarkers of tubular injury have long been sought to differentiate 
AKI-HRS and ATN in patients with cirrhosis [30].
There are many biomarkers released by tubular injury. Among these, NGAL has 
been the most widely studied biomarker in patients with cirrhosis and showed the 
greatest diagnostic accuracy in differentiating ATN from AKI-HRS [9]. Cut-off of 
0.2% has been widely used in distinguishing HRS from ATN [9]. Urinary NGAL 
seems to be superior to plasma concentrations and performs better when measured 
after the two-day volume challenge recommended in the management of any AKI 
including HRS [31].
At the current time human studies rely on expert adjudication for differentiat-
ing ATN from AKI-HRS owing to the limited availability of renal biomarkers and 
restricted use of kidney biopsies in such a high risk population.
5. Management of hepatorenal syndrome
HRS is one of the many causes of AKI in individuals with both acute and chronic 
liver disease. After correctly making a diagnosis of HRS, clinicians must address the 
underlying etiology of HRS. Patients that develop usually have cirrhosis, alcoholic 
hepatitis, liver failure, or fulminant hepatic failure from any etiology. Management 
of HRS is usually supportive, with the definitive treatment being reversal of the 
underlying liver pathology. In several patients, this means liver transplantation.
First line treatment of supportive management for HRS is using vasoconstric-
tors in combination with albumin to combat splanchnic arterial vasodilation [32]. 
The goal of treatment is to improve hemodynamic dysfunction by combatting the 
decreased circulating volume and increasing mean arterial pressure. The most 
common vasoconstrictors used are vasopressin analogues (terlipressin), norepi-
nephrine, and somatostatin analogues such as octreotide and midodrine.
6. Vasopressin analogues (terlipressin)
The vasopressin analogue Terilpressin is noted to have a greater affinity for the 
vasopressin 1 receptors in the splanchnic bed, it has been found to improve kidney 
Hepatorenal syndrome type 1 Hepatorenal syndrome type II
Rapid, progressive Insidious
Median survival <2 weeks Median survival 6 months
Table 2. 
Comparing Types of Hepatorenal Syndrome. Adopted from KDIGO guidelines [9, 21, 23].
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function in patients with HRS with a decreased incidence of ischemia as compared 
to vasopressin [33]. Studies have demonstrated that continuous administration of 
Terlipressin is better tolerated and associated with fewer adverse effects as com-
pared to intermittent bolus administration [34]. Continuous infusion of terlipressin 
in an outpatient setting has also been reported to be an effective, safe option of HRS 
treatment as a bridge to transplant [35, 36]. Terlipressin is considered as the first 
treatment of choice of HRS in Europe. Despite this fact, it is not currently approved 
by the Food and Drug Administration for use in the United States and Canada as a 
clear benefit of treatment in HSR has not been established.
Terlipressin was proven to be more effective than placebo in treating HRS type 1 
although terlipressin use was associated with more adverse events such abdominal 
pain, nausea, diarrhea and respiratory failure [37].
7. Norepinephrine
While Terilpressin is the traditional first choice for HRS, norepinephrine is 
another option clinician can use as vasoconstrictive therapy. One large meta-
analysis looking at randomized control trials in HRS compared the efficacy of 
various constrictive therapies. Terlipressin did demonstrate the most effective 
pressor to reverse HRS, but had an increased risk of adverse events. Norepinephrine 
was nearly as efficacious as Terlipressin, and although it was not able to provide the 
survival benefit as Terlipressin did have a better safety profile [38, 39].
8. Role of albumin
Albumin has a role in maintaining plasma oncotic pressure and detoxification. 
One of the few indications for albumin administration is HRS; with existing studies 
in the literature that report the efficacy of albumin in the treatment of HRS [40]. 
Although albumin has been proven to help in HRS, the optimal treatment dose has 
not yet been established in guidelines. One large meta-analysis study did demon-
strate a benefit with albumin, but optimal treatment dose with albumin has yet to 
be established. The study did demonstrate that a cumulative dose predicts a success-
ful response to therapy [41].
Current recommendation is to use both albumin with Terlipressin as it has been 
shown that it improves its beneficial effect when compared to using terlipressin 
alone or placebo [34, 42].
9. Transjugular intrahepatic portosystemic shunt
Transjugular intrahepatic portosystemic shunt (TIPS) is a treatment option for 
those patients who fail to respond to pharmacologic therapy. TIPS reduces portal 
pressures by placing a stent between the portal and hepatic vein. This decreases 
portal pressure and vascular resistance by reducing endothelin-1 [43, 44]. This pro-
cedure has shown to improve kidney function in patients with HRS with a reduction 
in serum blood urea nitrogen, serum creatinine, and urinary sodium excretion [45, 
46]. Although the TIPS procedure does improve elements of HRS, it was shown that 
there is limited evidence of survival benefit in patients with HRS [47] in addition to 
risk of development of hepatic encephalopathy which remains the greatest concern 
for clinicians. This is due to the portosystemic bypass shunt which results in bypass-




10. Renal replacement therapy
Renal replacement therapy (RRT) is an option for patients with HRS who 
progress to kidney failure and is most commonly done in patients awaiting liver 
transplant, or those with an acute reversible event. The role of RRT remains unclear 
due to lack of survival benefits as similar short term and long-term survival rates 
have been demonstrated as compared with non RRT treated patients [48].
11. Liver transplantation
HRS is an important entity in liver transplantation. Firstly, many patients wait-
ing for liver transplant will develop HRS. This is owing to the fact that the indica-
tion for liver transplant is often advanced cirrhosis or decompensated cirrhosis with 
ascites. These conditions may also predispose for HRS. The 1-year probability of 
developing HRS in the presence of ascites is 20%, and the 5-year probability is 40%. 
The patient population at highest risk of complications are those with fluid reten-
tion, which is seen in advanced and decompensated cirrhosis [49, 50].
Secondly, in patients who have HRS the therapies mentioned above such as vaso-
constrictors are used often as a bridge to transplantation. Therapies discussed above 
including vasoconstrictors may help, but the definitive treatment in HRS patients is 
often a transplant. Aggressive supportive care is unable to improve the recovery of 
kidney function in less than 50% of patients with HRS [50].
12. Simultaneous liver and kidney transplant
The concept of addressing HRS with a Simultaneous Liver and Kidney 
Transplant (SLKT) would seem to address both organ dysfunctions. However, HRS 
has the potential to be reversed by liver transplantation alone, and thus SLKT is not 
routinely considered in HRS. As mentioned in earlier sections, HRS is associated 
with many renal pathologies and it is possible for patients with HRS to develop end-
stage renal disease after liver transplant alone. Long wait times for liver transplan-
tation has led to a rise in the incidence of pre-transplantation renal dysfunction. 
The prolonged HRS and long-term RRT can lead to permanent renal damage. The 
permanent renal injury may lead to a decline in renal function that may not be 
adequate after liver transplant alone [42, 50].
13. Conclusion
HRS is not an uncommon entity in cirrhotic patients. It remains a challenge 
both diagnostically and in terms of management. Although there are many causes 
of renal impairment in the setting of cirrhosis, HRS is unique as the kidneys do 
not have an organic injury; rather they are a victim of poor circulation seen in 
advanced liver disease. Any renal impairment has the potential to increase mortal-
ity in the cirrhosis population, but HRS in particular is endangering to patients. 
There are two common forms of HRS, type 1 and type 2, and they can be generally 
distinguished based on acuity. There appears to be promise in the ease of diag-
nosis, with the advent of possible biomarkers; however, the present diagnosis is 
one of exclusion and can often be of challenge for clinicians. The management is 
mostly supportive care, with albumin and pressor playing a prominent role. The 
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